Calsarcin-1 protects against angiotensin-II-induced cardiac hypertrophy

被引:48
作者
Frank, Derk
Kuhn, Christian
van Eickels, Martin
Gehring, Doris
Hanselmann, Christiane
Lippl, Stefanie
Will, Rainer
Katus, Hugo A.
Frey, Norbert
机构
[1] Heidelberg Univ, Dept Internal Med 3, D-6900 Heidelberg, Germany
[2] Univ Klinikum Bonn, Med Univ Poliklin, Bonn, Germany
[3] Sanofi Aventis Pharma, Frankfurt, Germany
关键词
angiotensin; heart failure; hypertension; hypertrophy; myocardium;
D O I
10.1161/CIRCULATIONAHA.107.711317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-We have previously shown that deficiency for the z-disc protein calsarcin-1 (CS1) sensitizes the heart to calcineurin signaling and to stimuli of pathological hypertrophy. In the present study we asked whether overexpression of CS1 might exhibit antihypertrophic effects, and therefore we tested this hypothesis both in vitro and in vivo. Methods and Results-Adenoviral gene transfer of CS1 into neonatal cardiomyocytes inhibited hypertrophy as a result of Gq-agonist stimulation, including angiotensin-II (Ang-II), endothelin-1, and phenylephrine. Consistently, Adenoviral gene transfer of CS1 also led to the reduction of increased levels of atrial natriuretic factor (mRNA) and the calcineurin-sensitive gene MCIP1.4, suggesting that CS1 inhibits calcineurin-dependent signaling. Furthermore, we generated CS1-overexpressing transgenic mice (CS1Tg). Unchallenged CS1Tg mice did not exhibit a pathological phenotype as assessed by echocardiography and analysis of cardiac gene expression. Likewise, when subjected to long-term infusion of Ang-II, both CS1Tg and wild-type mice developed a similar degree of arterial hypertension. Yet, in contrast to wild-type mice, Ang-II-treated CS1Tg animals did not display cardiac hypertrophy. Despite the absence of hypertrophy, both fractional shortening and dP/dt(max) were preserved in CS1Tg Ang-II-treated mice as assessed by echocardiography and cardiac catherization, respectively. Moreover, induction of the hypertrophic gene program (atrial natriuretic factor, brain natriuretic peptide) was markedly blunted, and expression of the calcineurin-dependent gene MCIP1.4 was significantly reduced in CS1Tg mice, again consistent with an inhibitory role of CS1 on calcineurin. Conclusions-The sarcomeric protein CS1 prevents Ang-II-induced cardiomyocyte hypertrophy at least in part via inhibition of calcineurin signaling. Thus, overexpression of CS1 might represent a novel approach to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:2587 / 2596
页数:10
相关论文
共 42 条
[1]   MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure [J].
Arber, S ;
Hunter, JJ ;
Ross, J ;
Hongo, M ;
Sansig, G ;
Borg, J ;
Perriard, JC ;
Chien, KR ;
Caroni, P .
CELL, 1997, 88 (03) :393-403
[2]   Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice [J].
Bendall, JK ;
Cave, AC ;
Heymes, C ;
Gall, N ;
Shah, AM .
CIRCULATION, 2002, 105 (03) :293-296
[3]   Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload [J].
Brancaccio, M ;
Fratta, L ;
Notte, A ;
Hirsch, E ;
Poulet, R ;
Guazzone, S ;
De Acetis, M ;
Vecchione, C ;
Marino, G ;
Altruda, F ;
Silengo, L ;
Tarone, G ;
Lembo, G .
NATURE MEDICINE, 2003, 9 (01) :68-75
[4]   Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice [J].
Bueno, OF ;
Wilkins, BJ ;
Tymitz, KM ;
Glascock, BJ ;
Kimball, TF ;
Lorenz, JN ;
Molkentin, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (07) :4586-4591
[5]   A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway [J].
Bush, E ;
Fielitz, J ;
Melvin, L ;
Martinez-Arnold, M ;
McKinsey, TA ;
Plichta, R ;
Olson, EN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (09) :2870-2875
[6]   Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo [J].
De Windt, LJ ;
Lim, HW ;
Bueno, OF ;
Liang, QR ;
Delling, U ;
Braz, JC ;
Glascock, BJ ;
Kimball, TF ;
del Monte, F ;
Hajjar, RJ ;
Molkentin, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3322-3327
[7]   Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years [J].
Drazner, MH ;
Rame, JE ;
Marino, EK ;
Gottdiener, JS ;
Kitzman, DW ;
Gardin, JM ;
Manolio, TA ;
Dries, DL ;
Siscovick, DS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2207-2215
[8]   FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of skeletal muscle [J].
Faulkner, G ;
Pallavicini, A ;
Comelli, A ;
Salamon, M ;
Bortoletto, G ;
Ievolella, C ;
Trevisan, S ;
Kojic, S ;
Dalla Vecchia, F ;
Laveder, P ;
Valle, G ;
Lanfranchi, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) :41234-41242
[9]   The sarcomeric Z-disc: a nodal point in signalling and disease [J].
Frank, Derk ;
Kuhn, Christian ;
Katus, Hugo A. ;
Frey, Norbert .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (06) :446-468
[10]   Cardiac hypertrophy: The good, the bad and the ugly [J].
Frey, N ;
Olson, EN .
ANNUAL REVIEW OF PHYSIOLOGY, 2003, 65 :45-79